Frontier mental health research: psychedelics & drug studies

Key findings

• Most of the strongest clinical evidence for psychedelic treatment of PTSD comes from MDMA-assisted therapy, where larger trials showed big benefits. ^{15063 15078}
• There are far fewer high-quality clinical trials testing LSD specifically for PTSD than there are for MDMA or psilocybin. ^{15135 15085 15078}
• Classic psychedelics like LSD mainly act on the brain’s serotonin 2A receptor and often change perception and thinking during the experience. ^{15086 15050 15091}
• Lab and animal studies show classical psychedelics can boost neuroplasticity — meaning they help brain cells make new branches and connections — which might help therapy. ^{15050 15091}
• Human studies that measured blood BDNF, a protein sometimes used as a marker of brain plasticity, did not find clear increases after psychoplastogen drugs, so blood BDNF changes are not proven. ¹⁵¹²⁹
• Clinical trials done under medical supervision have generally reported favorable safety profiles, but that does not mean all risks are known. ^{15135 15087}
• Some psychedelics (for example, ibogaine) have serious physical risks such as heart problems, showing that safety differs across drugs. ^{15050 15085}
• Non-drug factors strongly shape outcomes: careful preparation, the therapy given during the session, and follow-up integration are important for both safety and benefit. ^{15065 15086 15063}
• Many trials are small and most study participants have been white, so we do not know if results apply to people of color or to larger, more varied populations. ^{15085 15095}
• Important open questions remain: whether the psychedelic experience itself is required for benefit, how long positive effects last, the best ways to deliver therapy, and long-term safety. ^{15078 15086 15091}